Gastric Cancer, Histone Deacetylase Inhibitor
Conditions
Keywords
gastric cancer, histone deacetylase inhibitor, 1st line chemotherapy
Brief summary
There is scientific rationale for exploring the role of vorinostat, histone deacetylase inhibitor with capecitabine (X) and cisplatin (P), one of standard chemotherapy in patients with advanced gastric cancer. XP is a new standard of care in advanced gastric cancer (AGC) and vorinostat is a novel targeted agent that prevents tumor cell proliferation, survival and angiogenesis through histone deacetylase inhibition.
Interventions
DRUGVorinostat, capecitabine, and cisplatin
Vorinostat 200\ 400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
Sponsors
Asan Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed unresectable or metastatic advanced gastric adenocarcinoma * Completion of adjuvant chemotherapy 6 months before the study, or no previous chemotherapy * Age 18 to 70 years old * Eastern Cooperative Oncology Group (ECOG) performance status 2 or less * Estimated life expectancy of more than 3 months * Presence of measurable or evaluable disease * Adequate bone marrow function (ANC \>1,500/µL and platelets\>100,000/µL), * Adequate renal function: creatinine \< 1 x upper normal limit (UNL) or creatinine clearance 60ml/min or less * Adequate hepatic function: bilirubin \< 1.5 x UNL, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels \< 2.5 x UNL (\< 5 x upper limit of normal for patients with liver involvement of their cancer), alkaline phosphatase \< 5 x UNL (except in case of bone metastasis without any liver disease) * Written informed consent
Exclusion criteria
* Prior exposure to any histone deacetylase (HDAC) inhibitor (however, valproic acid would be allowed if a 30-day wash-off period is provided.) * Previous adjuvant treatment with capecitabine or platinums * Contraindication to any drug contained in the chemotherapy regimen * Other tumor type than adenocarcinoma * Presence or history of central nervous system (CNS) metastasis * Gastric outlet or bowel obstruction * Evidence of serious gastrointestinal bleeding * Peripheral neuropathy \> grade 2 * History of significant neurologic or psychiatric disorders * History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix * Pregnant or lactating women, women of childbearing potential not employing adequate contraception * Active human immunodeficiency virus (HIV) infection * Viral hepatitis infections * Other serious illness or medical conditions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase 1 - maximum tolerated dose, Phase 2 - response rate | 3 weeks for maximum tolerated dose, and 6 months for response rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity profile | toxicity for each cycle | — |
| Progression-free survival | 1 year | Time from first administration of study drug to disease progression or any cause of death |
| Overall survival | 1 year | Time from first administration of study drug to any cause of death |
Countries
South Korea
Outcome results
None listed